La-ser Publications

Displayed below is a list of key LA-SER publications

To contact one of our authors, please email info@la-ser.com or call +44 203 1375 800

Grimaldi-Bensouda L, Aubrun E, Leighton P, Alpérovitch A, Benichou J, Rossignol M, Abenhaim L and Study Group. Agreement between patients’ self-report and medical records. Pharmacoepidemiology & Drug Safety, In press

Grimaldi-Bensouda L, Michel M, Viallard JF, Adoue D, Magy-Bertrand N, Khellaf M, Hacini M, Fain O, Morin AS, Quittet P, Pan-Petesch B, Bonnotte B, Chalumeau-Costedoat N, Ruel M, Leighton P, Aubrun E, Alperovitch A, Abenhaim L, Godeau B and the PGRx-ITP study group. . In press

Grimaldi-Bensouda L, Rossignol M, Aubrun E, Benichou J, Abenhaim L & Study Group. Agreement between patients’ self-report and physicians’ prescriptions study. Pharmacoepidemiol Drug Saf. 2012 Feb 7. doi: 10.1002/pds.3194.

Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): Applying the EVIDEM framework to medicines appraisal. Med Decis Making 2012;32(2):376–88.

S Thangaratinam, E Rogozińska, K Jolly, S Glinkowski,W Duda, E Borowiack,T Roseboom, M Merialdi, J Tomlinson, JWalczak, R Kunz, BW Mol,A Coomarasamy, KS Khan. Interventions to reduce or prevent obesity in pregnant women: A systematic review. Health Technology Assessment. 2012 ;16(31) :iii-iv, 1–191.

Ortega F, Otero A, Crespo JF, et al. Satisfaction and adherence with immunosuppressant treatment in renal transplant patients living with a working graft. J.Nephrol. 2012:0.

Torrelo A, Ortiz J, Alomar A, Ros S, Prieto M, Cuervo J. Atopic dermatitis: impact on quality of life and patients’ attitudes toward its management. Eur.J.Dermatol. 1/2012 2012;22(1):97–105.

Buckley BS, Harreiter J, Damm P, et al. Gestational diabetes mellitus in Europe: prevalence, current screening practice and barriers to screening. A review. Diabet.Med. 7/2012 2012;29(7):844–854.

Villa G, Fernandez-Ortiz L, Cuervo J, et al. Cost-effectiveness analysis of the Spanish renal replacement therapy program. Perit.Dial.Int. 3/2012 2012;32(2):192–199.

Villa G, Sanchez-Alvarez E, Cuervo J, Fernandez-Ortiz L, Rebollo P, Ortega F. Cost-effectiveness analysis of timely dialysis referral after renal transplant failure in Spain. BMC.Health Serv.Res. 8÷16÷2012 2012;12(1):257.

Espuna-Pons M, Castro-Diaz D, Diaz-Cuervo H, Perez M. Impact of Overactive Bladder Treatment on Associated Comorbidities. Actas Urol.Esp. 2÷23÷2012 2012.

Parra E, Arenas MD, Alonso M, et al. Outcomes weighting for comprehensive haemodialysis centre assessment. Nefrologia. 9÷26÷2012 2012;32(5):659–663.

Ma L, White R, Narayanan S, Schmader MD. Economic burden of herpes zoster among skilled nursing facility residents in the US. J Am Med Dir.Assoc. 2012 2012;13(1):54–59.

Grimaldi-Bensouda L, Rouillon F, Astruc B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophrenia research. Feb 2012;134(2–3):187–194.

Grimaldi-Bensouda L, Rossignol M, Aubrun E, Benichou J, Abenhaim L, the PSG. Agreement between patients’ self-report and physicians’ prescriptions on nonsteroidal anti-inflammatory drugs and other drugs used in musculoskeletal disorders: the international Pharmacoepidemiologic General Research eXtension database. Pharmacoepidemiology and drug safety. Jul 2012;21(7):753–759.

Rossignol M, Begaud B, Engel P, et al. Impact of physician preferences for homeopathic or conventional medicines on patients with musculoskeletal disorders: results from the EPI3-MSD cohort. Pharmacoepidemiology and drug safety. Oct 2012;21(10):1093–1101.

Casciano R, Wang X, Stern L, et al. International practice patterns and resource utilization in the treatment of neuroendocrine tumors. Pancreas. 2012 [Publication Pending].

Lee EK, Revil C, Ngoh CA, et al. Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea. Clin.Ther. 6/2012 2012;34(6):1408–1419.

Lister J, Stanisic S, Kaier K, Hagist C, Gultyaev D, Walzer S. Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain. Clinicoecon Outcomes Res. 2012 2012;4(in press).

Lister J, Stanisic S, Mueller E, Gultyaev D. Would Societal Costs in Health Economic Analyses Influence Decision Making? Hypothetical Analyses for Germany and France. Value Health. 2012 2012;15(4):A196.

Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): Applying the EVIDEM framework to medicines appraisal. Med.Decis.Making. 2012 2012;32(2):376–388.

Bennetts L, O’Neil W, Welner S, Tanois N. Understanding the Classes: Sulfonylureas for Type 2 Diabetes. Provincial Reimbursement Advisor. 2012 2012;15(2):51–57.

Bennetts L, Khoury H, O’Neil W, Welner S. Understanding the classes: disease-modifying drugs for multiple sclerosis. Provincial Reimbursement Advisor. 2012 2012;15(3):52–61.

Khoury H, O’Neil W, Welner S. Understanding the classes: biological response modifiers for psoriasis. Provincial Reimbursement Advisor. 2012 2012;15(1):48–55.

Grimaldi-Bensouda L, Begaud B, Lert F, Rouillon F, Massol J, Guillemot D, Avouac B, Duru G, Magnier AM, Rossignol M, Abenhaim L; for the EPI3-LASER Group. Benchmarking the burden of 100 diseases: results of a nationwide representative survey within general practices. BMJ Open. 2011 Nov 14;1(2).

Grimaldi-Bensouda L, Rossignol M, Danchin N, Steg PG, Bessede G, Ovize M, Cottin Y, Autret-Leca E, Benichou J, Abenhaim L et Study group Risk of ST versus non-ST elevation myocardial infarction (…). Heart. 2011 Nov;97(22):1834–40. Epub 2011 Aug 31.

Grimaldi-Bensouda L, Alpérovitch A, Besson G, Vial C, Cuisset JM, Papeix C, Lyon-Caen O, Benichou J, Rossignol M; Lucien Abenhaim for the GBS-PGRx Study Group. Study of Guillain-Barre syndrome (…). Am J Epidemiol. 2011 Aug 1;174(3):326–35. Epub 2011 Jun 7.

Casciano R, Malangone E, Ramachandran A, Gagliardino J. A quantitative assessment of patient barriers to insulin. International Journal of Clinical Practice. 2011; 65(4):408–414.

Tony M, Wagner M, Khoury H, Rindress D, Papastavros T, Oh P, et al. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEN framework for coverage decisions by a public payer in Canada. BMC Health Serv Res 2011;11(329):1–13.

 Khan KS, Borowiack E, Roos C, Kowalska M, Zapalska A,Mol BW,Mignini L,Meads C,Walczak J; EBM-CONNECT Collaboration.Making GRADE accessible: A proposal for graphic display of evidence quality assessments. Evid Based Med. 2011 Jun;16(3):65–9.

Koike T, Harigai M, Inokuma S, et al. Safety and effectiveness responses to etanercept for rheumatoid arthritis in Japan: a sub-analysis of a post-marketing surveillance study focusing on the duration of rheumatoid arthritis [Epub ahead of print]. Rheumatol.Int. 2011.

Moots R, Haraoui B, Matucci-Cerinic N, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol. 2011 2011;29(1):26–34.

Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res.Ther. 2011 2011;13(3):R75.

Zhang Q, Jameson K, Bolinder B, et al. Annual Medical Expenditure and Mortality Related to Acute Coronary Syndrome (ACS) in the United Kingdom — A Systematic Review. Value Health. 11/2011 2011;14(7):A375.

Grimaldi-Bensouda L, Rossignol M, Danchin N, et al. Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs. Heart. Nov 2011;97(22):1834–1840.

Khoury H, Welner S, Kubin M, Folkerts K, Haas S. Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in Europe show under-utilisation of preventive therapies. Thromb.Haemost. 2011 2011;106(4):600–608.

Ogilvie I, Welner S, Cowell W, Lip G. Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. Am J Cardiol. 2011 2011;108(1):151–161.

Ogilvie I, Welner S, Cowell W, Lip G. Ischemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients. Thromb.Haemost. 2011 2011;106(1):34–44.

Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L. Economic Impactof Enoxaparin After Acute Ischemic Stroke Based on PREVAIL. Clinical and Applied Thrombosis / Hemostasis. 3÷18÷2011 2011;17(2):150–157.

Seifert C, Lottmann K, Chen X, et al. Budget Impact Analyse von Dronedaron bei Behandlung von Patienten mit nicht-permanentem Vorhofflimmern aus Perspektive der GKV in Deutschland. Perfusion. 2011 2011;24(6):212–220.

Sato R, Milligan G, Molta C, Singh A. Health-related quality of life and healthcare resource use in European patients with plaque psoriasis: an association independent of observed disease severity. Clin Exp Dermatol. 1÷20÷2011 2011;36(1):24–28.

Casciano R, Malangone E, Ramachandran A, Gagliardino JJ. A quantitative assessment of patient barriers to insulin. Int J Clin Pract. Apr 2011;65(4):408–414.

Ogilvie I, Khoury H, El Khoury A, Goetghebeur M. Burden of rotavirus gastroenteritis in the pediatric population in central and eastern Europe: serotype distribution and burden of illness. Hum.Vaccin. 5/2011 2011;7(5):523–533.

Villa G, Rodriguez-Carmona A, Fernandez-Ortiz L, et al. Cost analysis of the Spanish renal replacement therapy programme. Nephrol.Dial.Transplant. 11/2011

Parra ME, Arenas Jimenez MD, Alonso M, et al. Multicentre study of haemodialysis costs. Nefrologia. 2011 2011;31(3):299–307.

Grimaldi-Bensouda L, Alperovitch A, Besson G, et al. Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. American journal of epidemiology. Aug 1 2011;174(3):326–335.

Rossignol M, Begaud B, Avouac B, et al. Benchmarking clinical management of spinal and non-spinal disorders using quality of life: results from the EPI3-LASER survey in primary care. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. Dec 2011;20(12):2210–2216.

Rossignol M, Begaud B, Avouac B, et al. Who seeks primary care for musculoskeletal disorders (MSDs) with physicians prescribing homeopathic and other complementary medicine? Results from the EPI3-LASER survey in France. BMC musculoskeletal disorders. 2011;12:21.

Ahn MJ, Tsai CM, Hsia TC, et al. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan. Asia-Pacific journal of clinical oncology. Jun 2011;7 Suppl 2:22–33.

Chang GC, Ahn MJ, Wright E, et al. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. Asia-Pacific journal of clinical oncology. Jun 2011;7 Suppl 2:34–40.

Chang JW, Thongprasert S, Wright E, et al. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. Asia-Pacific journal of clinical oncology. Jun 2011;7 Suppl 2:13–21.

Di Lorenzo G, Casciano R, Malangone E, et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert opinion on pharmacotherapy. Jul 2011;12(10):1491–1497.

Miravitlles M, Llor C, Calvo E, Diaz S, Diaz-Cuervo H, Gonzalez-Rojas N. [Validation of the Spanish version of the Chronic Obstructive Pulmonary Disease-Population Screener (COPD-PS). Its usefulness and that of FEV(1)/FEV(6) for the diagnosis of COPD.]. Med.Clin.(Barc.). 2011.

Tony M, Wagner M, Khoury H, et al. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Serv Res. 2011 2011;11(329):1–13.

Montejo AL, Lauffer JC, Cuervo J, et al. Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the ‘Tolerability and quality of life’ (TOOL) questionnaire. Ann.Gen.Psychiatry. 2011 2011;10:6.

Montejo AL, Correas-Lauffer J, Maurino J, et al. Estimation of a multiattribute utility function for the Spanish version of the TooL questionnaire. Value.Health. 6/2011 2011;14(4):564–570.

Grimaldi-Bensouda L, Begaud B, Lert F, et al. Benchmarking the burden of 100 diseases: results of a nationwide representative survey within general practices. BMJ open. 2011;1(2):e000215.

O’Neil W, Welner S, Guindo A. Understanding the classes: LHRH agonists for prostate cancer. Provincial Reimbursement Advisor. 5÷1÷2011 2011;14(2):46–53.

O’Neil B, Patel H, Welner S. Understanding the Classes: SSRIs and SNRIs for depression. Provincial Reimbursement Advisor. 2011 2011;14(3):50–56.

O’Neil W, Tony M, Welner S. Understanding the classes: cholinestrase inhibitors for dementia. Provincial Reimbursement Advisor. 2/2011 2011;14(1):55–62.

Tony M, Patel H, Welner S. Understanding the classes: statins. Provincial Reimbursement Advisor. 2011 2011;14(4):44–52.

Grimaldi-Bensouda L, Rossignol M, Aubrun E, El Kerri N, Benichou J, Abenhaim L; PGRx Study Group. Agreement between patients’ self-report and physicians’ prescriptions on cardiovascular drug exposure: the PGRx experience. Pharmacoepidemiol Drug Saf. 2010 Jun;19(6):591–5.

Grimaldi-Bensouda L, Marty M, Pollak M, Cameron D, Riddle M, Charbonnel B, Barnett AH, Boffetta P, Boivin JF, Evans M, Rossignol M, Benichou J, Abenhaim L; ISICA group. The international study of insulin and cancer. Lancet. 2010 Sep 4;376(9743):769–70.

Goetghebeur M, Wagner M, Khoury H, Rindress D, Gregoire J-P, Deal C. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision making framework to growth hormone for Turner syndrome patients. Cost Eff Resour Alloc 2010;8(1):4.

Kekow J, Moots R, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial. Ann.Rheum.Dis. 1÷1÷2010 2010;69(1):222–225.

Cozzi F, Tiso F, Lopatriello S, et al. The social costs of digital ulcer management in sclerodema patients: an observational Italian pilot study. Joint Bone Spine. 1/2010 2010;77(1):83–84.

Blumberg EA, Hauser IA, Stanisic S, et al. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation. 12/27/2010 2010;90(12):1420–1426.

Berenson K, Casciano R, Makenbaeva D, Mozaffari E, Lamerato L, Corbelli J. Economic Consequences of Severe Bleeding in Patients with Acute Coronary Syndrome in the USA. Advances in Therapy. July 29, 2010 2010;27(8):564–579.

Grimaldi-Bensouda L, Rossignol M, Aubrun E, et al. Agreement between patients’ self-report and physicians’ prescriptions on cardiovascular drug exposure: the PGRx database experience. Pharmacoepidemiology and drug safety. Jun 2010;19(6):591–595.

Ogilvie I, Newton N, Welner S, Cowell W, Lip G. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am.J.Med. 7/2010 2010;123(7):638–645.

Berto P, Inzitari D, Scrutinio D, et al. Clopidogrel Idrogenosolfato versus Aspirina nella Riduzione degli Eventi Aterotrombotici nelle popolazioni ad elevato rischio cardiovascolare: un’analisi italiana di costo-efficacia basata sul trial CAPRIE. PharmacoEconomics — Italian Research Articles. 2010 2010;12(1):1–18.

Pineo G, Lin J, Stern L, Subrahmanian T. Robust Univariate And Multivariate Sensitivity Analysis Confirm That Enoxaparin Is Cost-Saving To The Payers Compared With UFH For VTE Prevention In Patients With Ischemic Stroke: Analysis Of The Prevail Data. Foothills Hospital, University of Calgary, Calgary, Alberta, Canada sanofi-aventis U.S., Bridgewater, NJ, USA Analytica International, New York, NY, USA; 2010:2.

Grimaldi-Bensouda L, Abenhaim L, Michaud L, et al. Clinical features and risk factors for upper gastrointestinal bleeding in children: a case-crossover study. European journal of clinical pharmacology. Aug 2010;66(8):831–837.

Suzuki F, Akuta N, Suzuki Y, et al. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol.Hepatol. 5/2010 2010;25(5):892–898.

Autret-Leca E, Kreft-Jais C, Elefant E, et al. Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France. Drug Saf. Aug 1 2010;33(8):659–665.

Martinez AE, Ruiz Cerda JL, Gomez PL, Rebollo P, Perez M, Chaves J. [Impact of urinary incontinence and overactive bladder syndrome on health-related quality of life of working middle-aged patients and institutionalized elderly patients]. Actas Urol.Esp. 3/2010 2010;34(3):242–250.

Martinez-Agullo E, Ruiz Cerda JL, Arlandis GS, Rebollo P, Perez M, Chaves J. [Analysis of overactive bladder and urinary incontinence in males in the age range between 50 and 65 years. EPICC study]. Actas Urol.Esp. 6/2010 2010;34(6):543–548.

Martinez-Agullo E, Ruiz-Cerda JL, Arlandis S, Rebollo P, Perez M, Chaves J. [Analysis of overactive bladder and urinary incontinence in working women aged between 25 and 64 years. EPICC study]. Actas Urol.Esp. 7/2010 2010;34(7):618–624.

Arenas MD, Rebollo P, Malek T, et al. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J.Nephrol. 11/2010 2010;23(6):683–692.

Espuna-Pons M, Blasco P, Perez M, Diaz-Cuervo H. [Association between nocturia, subjective satisfaction with sleep and insomnia in patients with overactive bladder]. Med.Clin.(Barc.). 9÷11÷2010 2010;135(8):357–359.

Espuna-Pons M, Blasco P, Perez M, Rebollo P. Nocturia in patients with overactive bladder. Arch.Esp Urol. 6/2010 2010;63(5):363–372.

Berto P, Antonelli M, Ronco C, Cruz D, Melotti RM. Cost-Effectiveness Of Polymyxin B Immobilized Fiber Column And Conventional Medical Therapy In The Management Of Severe Abdominal Sepsis In Italy. Value in Health. 2010 2010;13(3):A5.

Berto P, Maggi S, Noale M, Lopatriello S. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis. Aging Clin.Exp.Res. 2÷9÷2010 2010.

Grimaldi-Bensouda L, Marty M, Pollak M, et al. The international study of insulin and cancer. Lancet. Sep 4 2010;376(9743):769–770. colorectal cancer in South Korea. Clin.Ther. 6/2012 2012;34(6):1408–1419.

Lewis G, Peake M, Aultman R, et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J.Int.Med.Res. 1/2010 2010;38(1):9–21.

Mueller E. Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). Lung Cancer. 8/2010 2010;69 Suppl 1:S1-S3.

Mueller E, Nuijten M, Ravera S, Stanisic S, Walzer S. Societal Cost Savings Associated with Bevacizumab-Based Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients in Italy. Value Health. 2010 2010;13(7):A271-A272.

Schmidt E, Bischoff HG, Heigener DF, Stanisic S, Walzer S. Cost Savings Associated with Bevacizumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer (NSSCLC) in Germany. Value Health. 2010 2010;13(7):A271.

Schmidt E, Stanisic S, Neumann M, Walzer S. Indirect Cost in Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review. Value Health. 2010 2010;13(7):A271.

Stanisic S, Bischoff HG, Heigener DF, et al. Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). Lung Cancer. 8/2010 2010;69 Suppl 1:S24-S30.

Stanisic S, Castro Carpeño JD, Walzer S. First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) with Bevacizumab and Societal Cost Savings in Spain. Value Health. 2010 2010;13(7):A271.

Stanisic S, Vergnenegre A, Chouaid C, Mueller E, Walzer S. Societal Cost Savings in Metastatic Non-Small Cell Lung Cancer (NSCLC) in France. Value Health. 2010 2010;13(7):A271.

Weber MM, Lister J, Reichelt C, Pulgar S, Arora S, Berenson K. A Cost-Consequence Model for Octreotide LAR as Treatment for Metastatic Midgut NET. Ann Oncol. 2010 2010;21(Suppl 8):viii267.

Rebollo P, Cuervo J, Villa G, et al. [Development and validation of a generic questionnaire for evaluating satisfaction in patients with chronic disease: the SAT-Q Questionnaire]. Aten.Primaria. 12/2010 2010;42(12):612–619.

Rebollo P, Castejon I, Cuervo J, et al. Validation of a computer-adaptive test to evaluate generic health-related quality of life. Health Qual.Life Outcomes. 2010 2010;8:147.

Berto P, Breccia M, Latagliata R. Analisi costo-efficacia di dasatinib, nella prospettiva del SSN Italiano. Giornale Italiano di Health Technology Assessment. 2010 2010;3(1):1–17.

Goetghebeur M, Wagner M, Khoury H, Rindress D, Gregoire J-P, Deal C. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients. Cost.Eff.Resour.Alloc. 4÷8÷2010 2010;8(1):4.

Bennetts L, O’Neil W, Welner S, Tanois N. Understanding the Classes: Sulfonylureas for Type 2 Diabetes. Provincial Reimbursement Advisor. 2012 2012;15(2):51–57.

Welner S, Rindress D, Tony M. Understanding the classes: oral long-acting opioids for pain. Provincial Reimbursement Advisor. 2010 2010;13(1):52–61.

O’Neil W, Tony M, Welner S. Understanding the classes: aromastase inhibitors as adjuvant therapy for breast cancer. Provincial Reimbursement Advisor. 2010 2010;13(4):46–53.

Ogilvie I, Welner S. Understanding the classes: biological response modifiers for rheumatoid arthritis. Provincial Reimbursement Advisor. 2010 2010;13(3):51–63.

Ogilvie I, Welner S. Understanding the classes: inhaled beta2-adrenergic agonists. Provincial Reimbursement Advisor. 5/2010 2010;13(2):49–61.